Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 6;27(23):8596.
doi: 10.3390/molecules27238596.

Challenges in Preparation of Albumin Nanoparticle-Based Radiopharmaceuticals

James R Ballinger  1
Affiliations
Review

Challenges in Preparation of Albumin Nanoparticle-Based Radiopharmaceuticals

James R Ballinger. Molecules. .

Abstract

Albumin nanocolloids have been used as radiopharmaceuticals for more than 40 years. Their main use is in lymphoscintigraphy and the detection of the sentinel lymph node as part of the surgical treatment of a variety of solid tumours. The main licensed products are labelled with the gamma emitter technetium-99m. Recently, two analogues labelled with positron emitters have been reported, using gallium-68 and zirconium-89. For about 10 years, there has been interest in dual-modal agents with both radioactive and fluorescent labels to improve the localisation of the sentinel lymph node. Indocyanine green (ICG) has been the most widely used fluorescent label, largely due to its availability as a licensed agent and its ease of application. The further development of alternative radiolabels or improved fluorescent tags will require investment in the development and licensing. There is also a vast potential for the targeting of albumin nanocolloids using existing strategies, which could be promising for the development of both diagnostic and therapeutic agents.

Keywords: gallium-68; human serum albumin; indocyanine green; nanocolloid; sentinel lymph node; technetium-99m; zirconium-89.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Graphical representation of the sequence of steps in preparation and radiolabelling of HAS-NC and its dual-modality analogue.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Shen X., Liu X., Li T., Chen Y., Chen Y., Wang P., Zheng L., Yang H., Wu C., Deng S., et al. Recent Advancements in Serum Albumin-Based Nanovehicles toward Potential Cancer Diagnosis and Therapy. Front. Chem. 2021;9:746646. doi: 10.3389/fchem.2021.746646. - DOI - PMC - PubMed
    1. Hornok V. Serum Albumin Nanoparticles: Problems and Prospects. Polymers. 2021;13:3759. doi: 10.3390/polym13213759. - DOI - PMC - PubMed
    1. Chen L., Xu N., Wang P., Zhu H., Zhang Z., Yang Z., Zhang W., Guo H., Lin J. Nanoalbumin–Prodrug Conjugates Prepared via a Thiolation-and-Conjugation Method Improve Cancer Chemotherapy and Immune Checkpoint Blockade Therapy by Promoting CD8+ T-Cell Infiltration. Bioeng. Transl. Med. 2022. e10377. early view . - DOI - PMC - PubMed
    1. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O’Shaughnessy J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer. J. Clin. Oncol. 2005;23:7794–7803. doi: 10.1200/JCO.2005.04.937. - DOI - PubMed
    1. Sofias A.M., Dunne M., Storm G., Allen C. The Battle of “Nano” Paclitaxel. Adv. Drug Deliv. Rev. 2017;122:20–30. doi: 10.1016/j.addr.2017.02.003. - DOI - PubMed

LinkOut - more resources